Table 1.

Patient characteristics and comparison of characteristics and outcome to NAC between patients with and without EpCAM-positive CTC(s) and patients with and without MCAM-positive CTC(s)

EpCAM-positive CTCs at baselineMCAM-positive CTCs at baselineEpCAM- and/or MCAM-positive CTCs at baseline
Clinicopathologic variable at diagnosisAll patientsNo CTCs≥1 CTCP valueNo CTCs≥1 CTCP valueNo CTCs≥1 CTCP value
n6856126085117
Age at diagnosis (years ± SD)51.2 ± 7.751.4 ± 7.949.9 ± 6.80.5451.4 ± 7.849.8 ± 7.60.5951.5 ± 8.050.2 ± 7.00.55
Clinical tumor classification before NAC
 cT244 (65%)36 (64%)8 (67%)0.8840 (67%)4 (50%)0.3535 (69%)9 (53%)0.24
 cT3 or cT424 (35%)20 (36%)4 (33%)20 (33%)4 (50%)16 (31%)8 (47%)
Clinical lymph node classification before NAC
 cN039 (57%)33 (59%)6 (50%)0.5735 (58%)4 (50%)0.6531 (61%)8 (47%)0.32
 cN+29 (43%)23 (41%)6 (50%)25 (42%)4 (50%)20 (39%)9 (53%)
Histological subtype
 Ductal37 (54%)28 (50%)9 (75%)0.5730 (50%)7 (88%)0.3824 (47%)13 (76%)0.26
 Lobular13 (19%)12 (21%)1 (8%)13 (22%)012 (23%)1 (6%)
 Other7 (10%)6 (11%)1 (8%)6 (10%)1 (12%)5 (10%)2 (12%)
 Unknowna11 (16%)10 (18%)1 (8%)11 (18%)010 (20%)1 (6%)
Hormone receptor expression
Estrogen receptor
  Positive57 (84%)46 (82%)11 (92%)0.4250 (83%)7 (88%)0.7642 (82%)15 (88%)0.57
Progesterone receptor
  Positive45 (66%)36 (64%)9 (75%)0.4838 (63%)7 (88%)0.1832 (63%)13 (77%)0.30
Menopausal status
 Pre/perimenopausal35 (52%)29 (52%)6 (50%)0.8831 (52%)4 (50%)0.9327 (53%)8 (47%)0.75
 Postmenopausal32 (47%)26 (46%)6 (50%)28 (47%)4 (50%)23 (45%)9 (53%)
 Unknown1 (1%)1 (2%)01 (2%)01 (2%)0
Treatment received
 TAC33 (49%)27 (48%)6 (50%)0.9130 (50%)3 (38%)0.5125 (49%)8 (47%)0.89
 TAC + ZA35 (51%)29 (52%)6 (50%)30 (50%)5 (62%)26 (51%)9 (53%)
Pathologic complete response to NAC
 Yes14 (21%)12 (21%)2 (17%)0.7114 (23%)00.1312 (24%)2 (12%)0.30
 No54 (79%)44 (79%)10 (83%)46 (77%)8 (100%)39 (76%)15 (88%)

NOTE: Reported P values are from Student t tests for age and Pearson χ2 for all other categorical variables.

  • aNot enough tumor cells left after NAC for reliable histological subtyping.